Safety and efficacy of non–vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial
ConclusionsA bivariate analysis that simultaneously characterizes both risk and benefit demonstrates that riva- and dabi-based regimens were both favorable over VKA plus dual antiplatelet therapy among patients with atrial fibrillation undergoing PCI.
Source: American Heart Journal - Category: Cardiology Source Type: research
More News: Angioplasty | Aspirin | Atrial Fibrillation | Bleeding | Cardiology | Coronary Angioplasty | Heart | Heart Attack | Percutaneous Coronary Intervention | Pradaxa | Stroke | Thrombosis | Vitamin K | Vitamins